Type 2 diabetes

Type 2 diabetes

Patent Application for Treating Metabolic Disorders with Antagonistic Binding Proteins for GIPR/GLP-1 Receptor Agonist Fusion Proteins

Researchers have developed a novel approach to treating metabolic disorders by fusing a GLP-1 receptor agonist polypeptide with an antagonist glucose-dependent insulinotropic polypeptide receptor (GIPR) antigen binding protein. This fusion protein has shown promise in reducing body weight, improving insulin sensitivity, and promoting glucose tolerance. According to the patent application,